Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2016

Open Access 01-07-2016 | Clinical trial

HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients

Authors: Sasagu Kurozumi, Mary Padilla, Masafumi Kurosumi, Hiroshi Matsumoto, Kenichi Inoue, Jun Horiguchi, Izumi Takeyoshi, Tetsunari Oyama, Jim Ranger-Moore, D. Craig Allred, Eslie Dennis, Hiroaki Nitta

Published in: Breast Cancer Research and Treatment | Issue 1/2016

Login to get access

Abstract

HER2 gene-protein assay (GPA) is a new method for the simultaneous evaluation of HER2 immunohistochemistry (IHC) and HER2 dual in situ hybridization (DISH) on single tissue sections of breast cancer. We investigated the presence of HER2 gene and protein discrepancy and HER2-heterogeneity using HER2-GPA. HER2 status was analyzed for the correlation between the presence of HER2-heterogeneity and patient prognosis. Consecutive 280 invasive breast cancer were examined. Statuses of HER2 protein and gene were evaluated in whole tumor sections of HER2 GPA slides. HER2 protein and gene combination patterns were classified to six phenotypic and genotypic types for each case, as well as at individual cell levels: (A) IHC and DISH positive; (B) IHC positive and DISH negative; (C) IHC equivocal and DISH positive; (D) IHC equivocal and DISH negative; (E) IHC negative and DISH positive; and (F) IHC and DISH negative. The presence of HER2-heterogeneity was determined by the existence of at least two of six types within one tumor. HER2-IHC positive patients had significantly worse survival than IHC negative patients and HER2-DISH positive patients had significantly worse survival than DISH negative patients. HER2 IHC negative and DISH positive patients had significantly worse recurrence-free survival than IHC and DISH negative patients. In the HER2 IHC and DISH negative group, the HER2 heterogeneous group had significantly worse survival than the nonheterogeneous group. Notably, among triple negative breast cancer (TNBC), the HER2 heterogeneous group had significantly worse survival than the nonheterogeneous group. Our study suggests that the presence of HER2-heterogeneity might be a prognostic factor in HER2 negative breast cancer patients, especially in TNBC.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917CrossRefPubMed
2.
3.
Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505–516CrossRefPubMed
4.
Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16:1647–1655CrossRefPubMedPubMedCentral
5.
Francis GD, Jones MA, Beadle GF, Stein SR (2009) Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome. Diagn Mol Pathol 18:88–95CrossRefPubMed
6.
Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, Murillo AE, Gaire F, Farrell M et al (2008) Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol 3:41CrossRefPubMedPubMedCentral
7.
Nitta H, Kelly BD, Padilla M, Wick N, Brunhoeber P, Bai I et al (2012) A gene-protein assay for human epidermal growth factor receptor 2 (HER2): brightfield tricolor visualization of HER2 protein, the HER2 gene, and chromosome 17 centromere (CEN17) in formalin-fixed, paraffin-embedded breast cancer tissue sections. Diagn Pathol 7:60CrossRefPubMedPubMedCentral
8.
Zaczek A, Brandt B, Bielawski KP (2005) The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol 20:1005–1015PubMed
9.
Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE (2000) ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)–Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol Cell Biol 20:3210–3223CrossRefPubMedPubMedCentral
10.
Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, Seshagiri S et al (2012) Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 18:3478–3486CrossRefPubMed
11.
12.
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743CrossRefPubMed
13.
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109–119CrossRefPubMed
14.
Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783–1791CrossRefPubMed
15.
Paik S, Kim C, Wolmark N (2008) HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 358:1409–1411CrossRefPubMed
16.
Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG et al (2013) Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst 105:1782–1788CrossRefPubMedPubMedCentral
17.
Fehrenbacher L, Jeong J-H, Rastogi P, Geyer CE, Paik S, Costantino JP et al (2011) NSABP B-47: a randomized phase III trial of adjuvant therapy comparing chemotherapy alone (six cycles of docetaxel plus cyclophosphamide or four cycles of doxorubicin plus cyclophosphamide followed by weekly paclitaxel) to chemotherapy plus trastuzumab in women with node-positive or high-risk node-negative HER2-low invasive breast cancer. Cancer Res 71:OT1-02-07
18.
Hanna WM, Rüschoff J, Bilous M, Coudry RA, Dowsett M, Osamura RY et al (2014) HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Mod Pathol 27:4–18CrossRefPubMed
19.
Cottu PH, Asselah J, Lae M, Pierga JY, Diéras V, Mignot L, Sigal-Zafrani B, Vincent-Salomon A (2008) Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 19:595–597CrossRefPubMed
20.
Seol H, Lee HJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Park SY (2012) Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol 25:938–948CrossRefPubMed
21.
Lee HJ, Seo AN, Kim EJ, Jang MH, Suh KJ, Ryu HS et al (2014) HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. Am J Clin Pathol 142:755–766CrossRefPubMed
22.
Ohlschlegel C, Zahel K, Kradolfer D, Hell M, Jochum W (2011) HER2 genetic heterogeneity in breast carcinoma. J Clin Pathol 64:1112–1116CrossRefPubMed
23.
Shafi H, Astvatsaturyan K, Chung F, Mirocha J, Schmidt M, Bose S (2013) Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis. J Clin Pathol 66:649–654CrossRefPubMed
24.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182CrossRefPubMed
25.
Venter DJ, Tuzi NL, Kumar S, Gullick WJ (1987) Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 2:69–72CrossRefPubMed
26.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013
27.
Li Z, Dabbs DJ, Cooper KL, Bhargava R (2015) Dual HER2 gene protein assay: focused study of breast cancers with 2+ immunohistochemical expression. Am J Clin Pathol 143:451–458CrossRefPubMed
28.
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684CrossRefPubMed
29.
Negri T, Tarantino E, Orsenigo M, Reid JF, Gariboldi M, Zambetti M, Pierotti MA, Pilotti S (2010) Chromosome band 17q21 in breast cancer: significant association between beclin 1 loss and HER2/NEU amplification. Genes Chromosomes Cancer 49:901–909CrossRefPubMed
30.
Reinholz MM, Bruzek AK, Visscher DW, Lingle WL, Schroeder MJ, Perez EA et al (2009) Breast cancer and aneusomy 17: implications for carcinogenesis and therapeutic response. Lancet Oncol 10:267–277CrossRefPubMed
31.
Dal Lago L, Durbecq V, Desmedt C, Salgado R, Verjat T, Lespagnard L et al (2006) Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther 5:2572–2579
32.
Vranic S, Teruya B, Repertinger S, Ulmer P, Hagenkord J, Gatalica Z (2011) Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17. Cancer 117:48–53CrossRefPubMed
33.
Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323–1333CrossRefPubMed
34.
Bose S, Mohammed M, Shintaku P, Rao PN (2001) Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. Breast J 5:337–344CrossRef
35.
Cuadros M, Cano C, López FJ, Talavera P, García-Peréz I, Blanco A et al (2011) HER2 status in breast cancer: experience of a Spanish National Reference Centre. Clin Transl Oncol 13:335–340CrossRefPubMed
36.
Downs-Kelly E, Yoder BJ, Stoler M, Tubbs RR, Skacel M, Grogan T, Roche P, Hicks DG (2005) The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol 29:1221–1227CrossRefPubMed
37.
Kokate P, Sawaimoon S, Bhatia S, Mandava S (2012) Evaluation of genetic status of HER-2/neu and aneusomy 17 by fluorescence in situ hybridization and comparison with immunohistochemistry assay from Indian breast cancer patients. Genet Test Mol Biomarkers 16:239–245CrossRefPubMed
38.
Hofmann M, Stoss O, Gaiser T, Kneitz H, Heinmöller P, Gutjahr T et al (2008) Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 61:89–94CrossRefPubMed
39.
Krishnamurti U, Hammers JL, Atem FD, Storto PD, Silverman JF (2009) Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinoma. Mod Pathol 22:1044–1048CrossRefPubMed
40.
Merola R, Mottolese M, Orlandi G, Vico E, Cognetti F, Sperduti I, Fabi A, Vitelli G, Cianciulli AM (2006) Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer 42:1501–1506CrossRefPubMed
41.
Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C et al (2005) Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res 7:R267–R273CrossRefPubMedPubMedCentral
42.
Takehisa M, Sasa M, Bando Y, Hirose T, Morimoto T, Nagao T et al (2007) Chromosomal aneusomy (chr 1, 11, 17) detected by fluorescence in situ hybridization may be a prognostic factor in breast cancer. Anticancer Res 27:1073–1078PubMed
43.
Torrisi R, Rotmensz N, Bagnardi V, Viale G, Curto BD, Dell’orto P et al (2007) HER2 status in early breast cancer: relevance of cell staining patterns, gene amplification and polysomy 17. Eur J Cancer 43:2339–2344CrossRefPubMed
44.
Tsukamoto F, Miyoshi Y, Egawa C, Kasugai T, Takami S, Inazawa J et al (2001) Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization. Cancer 93:165–170CrossRefPubMed
45.
Tubbs RR, Hicks DG, Cook J, Downs-Kelly E, Pettay J, Hartke MB et al (2007) Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol 16:207–210CrossRefPubMed
46.
Vanden Bempt I, Van Loo P, Drijkoningen M, Neven P, Smeets A, Christiaens MR et al (2008) Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. J Clin Oncol 26:4869–4874
47.
Varshney D, Zhou YY, Geller SA, Alsabeh R (2004) Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol 121:70–77CrossRefPubMed
48.
Zaczek A, Markiewicz A, Supernat A, Bednarz-Knoll N, Brandt B, Seroczyńska B et al (2012) Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer. Pathol Oncol Res 18:885–894CrossRefPubMed
49.
Zhu X, Lu Y, Lu H, Yang W, Tu X, Cai X et al (2011) Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer. Hum Pathol 42:1499–1504CrossRefPubMed
50.
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4014CrossRefPubMed
51.
Vance GH, Barry TS, Bloom KJ, Fitzgibbons PL, Hicks DG, Jenkins RB et al (2009) Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 133:611–612PubMed
52.
Allison KH, Dintzis SM, Schmidt RA (2011) Frequency of HER2 heterogeneity by fluorescence in situ hybridization according to CAP expert panel recommendations: time for a new look at how to report heterogeneity. Am J Clin Pathol 136:864–871CrossRefPubMed
53.
Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728CrossRefPubMed
54.
Sweeney C, Bernard PS, Factor RE, Kwan ML, Habel LA, Quesenberry CP Jr et al (2014) Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer Epidemiol Biomarkers Prev 23:714–724CrossRefPubMedPubMedCentral
Metadata
Title
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
Authors
Sasagu Kurozumi
Mary Padilla
Masafumi Kurosumi
Hiroshi Matsumoto
Kenichi Inoue
Jun Horiguchi
Izumi Takeyoshi
Tetsunari Oyama
Jim Ranger-Moore
D. Craig Allred
Eslie Dennis
Hiroaki Nitta
Publication date
01-07-2016
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2016
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-016-3856-2

Other articles of this Issue 1/2016

Breast Cancer Research and Treatment 1/2016 Go to the issue

Epidemiology

Plasma fluorescent oxidation products and risk of estrogen receptor-negative breast cancer in the Nurses’ Health Study and Nurses’ Health Study II

Epidemiology

Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study

Clinical trial

A randomized, double-blind, crossover trial comparing a silicone- versus water-based lubricant for sexual discomfort after breast cancer

Epidemiology

Measured adolescent body mass index and adult breast cancer in a cohort of 951,480 women

Preclinical study

Stromal cells in phyllodes tumors of the breast are enriched for EZH2 and stem cell marker expression

Clinical trial

Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits